SLC5A2 and focal segmental glomerulosclerosis: However, recently published results of clinical trials revealed that the therapeutic potential of SGLT2 inhibitors extends to patients with IgAN [13] and focal segmental glomerulosclerosis (FSGS) with reduced proteinuria and eGFR decline [8, 14].